Baxter International (NYSE:BAX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Baxter International (NYSE:BAX) issued its quarterly earnings data on Friday. The medical instruments supplier reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02, Briefing.com reports. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The business had revenue of $3.85 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter last year, the business posted $0.68 EPS. The firm’s revenue was up 3.8% compared to the same quarter last year.

Baxter International Stock Performance

Shares of Baxter International stock traded down $1.40 during trading on Friday, hitting $34.64. 6,636,750 shares of the stock were exchanged, compared to its average volume of 4,048,272. Baxter International has a 1-year low of $32.48 and a 1-year high of $44.01. The stock has a market capitalization of $17.67 billion, a price-to-earnings ratio of 7.13, a price-to-earnings-growth ratio of 1.21 and a beta of 0.60. The company has a fifty day moving average price of $37.39 and a 200-day moving average price of $36.12. The company has a current ratio of 1.40, a quick ratio of 0.91 and a debt-to-equity ratio of 1.35.

Wall Street Analysts Forecast Growth

BAX has been the topic of a number of research analyst reports. Citigroup raised their price target on Baxter International from $38.00 to $40.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. StockNews.com raised shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. lowered their price objective on shares of Baxter International from $44.00 to $42.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Morgan Stanley cut shares of Baxter International from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $39.00 to $30.00 in a research report on Monday, July 15th. Finally, Wells Fargo & Company dropped their price target on Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Baxter International currently has a consensus rating of “Hold” and a consensus price target of $41.20.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.